However, more than 50% PD-L1 tumor cell expression in non small cell lung cancer patients predicts higher effectiveness of pembrolizumab as a first-line treatment compared to the effectiveness of chemotherapy. Here, CD274 is linked to non-small cell lung carcinoma.